8-K: Liquidia Secures Final FDA Approval for YUTREPIA, Paving Way for Commercial Launch in Pulmonary Hypertension

Liquidia Corporation announced today that its YUTREPIA (treprostinil) inhalation powder has received final U.S. FDA approval for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), following the expiration of United Therapeutics' Tyvaso DPI exclusivity.

Summary

• Liquidia Corporation received final U.S. Food and Drug Administration (FDA) approval for YUTREPIA (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
• The approval follows the expiration of the New Clinical Investigation exclusivity granted to United Therapeutics Corporation's Tyvaso DPI on May 23, 2025, which had previously delayed YUTREPIA's final approval.
• YUTREPIA is the first and only prostacyclin dry-powder formulation utilizing Liquidia's proprietary PRINT technology, designed for enhanced deep-lung delivery with an easy-to-use, low-effort device.
• The approval is supported by findings from the Phase 3 INSPIRE trial, which demonstrated YUTREPIA's safety and tolerability in both treprostinil-naive patients and those transitioning from nebulized treprostinil.
• Liquidia intends to begin commercializing YUTREPIA as soon as possible and will host a webcast on May 27, 2025, to provide an update on launch preparations.
• Despite the approval, ongoing and potential future litigation initiated by United Therapeutics, alleging infringement of U.S. Patent No. 11,357,782, may prevent or delay YUTREPIA's commercialization or require royalty payments.
• PAH affects an estimated 45,000 patients in the U.S., while PH-ILD affects over 60,000 patients in the U.S.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the final FDA approval of YUTREPIA, a major de-risking event and a significant step towards commercialization. This is tempered by the ongoing patent litigation which poses a material risk to the timing and profitability of the launch.

Positives

• Final FDA approval for YUTREPIA (treprostinil) inhalation powder for PAH and PH-ILD, a significant regulatory milestone.
• YUTREPIA is the first and only prostacyclin dry-powder formulation, offering a new treatment option for patients.
• The product utilizes Liquidia's proprietary PRINT technology, designed for enhanced deep-lung delivery and an easy-to-use device requiring low inspiratory effort, potentially improving patient adherence.
• Clinical data from the Phase 3 INSPIRE trial demonstrated YUTREPIA's safety and tolerability.
• The expiration of United Therapeutics' Tyvaso DPI exclusivity removes a key regulatory hurdle.
• The target patient populations (PAH and PH-ILD) are substantial, with over 105,000 patients combined in the U.S.

Negatives

• Ongoing litigation with United Therapeutics Corporation (UTHR) alleging patent infringement (U.S. Patent No. 11,357,782) could block or delay YUTREPIA's commercialization.
• The litigation may also result in Liquidia being required to pay damages, including royalties, in connection with its commercial launch.
• UTHR has filed a motion for temporary restraining order and preliminary injunction to block the commercial launch, which remains pending with the Court.

Risks

• Commercialization of YUTREPIA may be blocked or delayed due to ongoing or future legal proceedings, specifically the patent infringement lawsuit filed by United Therapeutics.
• Liquidia may be required to pay damages, including royalties, if the litigation is unsuccessful.
• The market acceptance of YUTREPIA and its potential pricing and/or reimbursement by third-party payors are uncertain.
• Future competitive or other market factors may adversely affect the commercial potential for YUTREPIA.
• The company operates in a very competitive and rapidly changing environment with inherent industry risks.

Future Outlook

Liquidia intends to begin commercializing YUTREPIA for the treatment of PAH and PH-ILD as soon as possible after obtaining final FDA approval. However, ongoing and potential future litigation may prevent or delay successful commercialization or require the company to pay damages or royalties. The company will provide an update on commercial launch preparations via a webcast on May 27, 2025.

Management Comments

• Dr. Roger Jeffs, CEO of Liquidia, stated: "Today, we celebrate for the patients and physicians who will now have access to a potential best-in-class dry-powder form of treprostinil with exceptional portability, tolerability, titratability and durability."
• Dr. Nicholas Hill, Principal Investigator on the Phase 3 INSPIRE study, expressed confidence in YUTREPIA's safety, tolerability, and dosing, noting that the low-effort inhalation device may make it easier to start and maintain patients on treatment.
• Matt Granato, President and CEO of the Pulmonary Hypertension Association, welcomed the expansion of treatment options for the PAH and PH-ILD patient communities, emphasizing the need for therapies that improve quality of life.

Industry Context

The approval of YUTREPIA introduces a new, differentiated treatment option into the pulmonary hypertension market, specifically for PAH and PH-ILD, which collectively affect over 105,000 patients in the U.S. This approval positions Liquidia as a direct competitor to United Therapeutics' Tyvaso DPI, which previously held exclusivity. YUTREPIA's unique dry-powder formulation and low-effort device could offer a competitive advantage in patient convenience and adherence within the prostacyclin analog class.

Comparison to Industry Standards

• YUTREPIA is a dry-powder formulation of treprostinil, differentiating it from nebulized treprostinil products like United Therapeutics' Tyvaso.
• YUTREPIA's PRINT technology is designed to enhance deep-lung delivery, potentially offering improved drug deposition compared to other inhaled therapies.
• The device for YUTREPIA requires low inspiratory effort, which may make it easier for patients with compromised lung function or limited inspiratory flows to use, potentially offering an advantage over devices requiring higher effort.
• The INSPIRE study evaluated patients transitioning from nebulized treprostinil (like Tyvaso), indicating YUTREPIA's potential as a switch option for existing patients.

Legal Proceedings

• United Therapeutics Corporation filed a complaint on May 9, 2025, in the U.S. District Court for the Middle District of North Carolina (Case No. 1:25-cv-00368) against Liquidia.
• The complaint alleges infringement of U.S. Patent No. 11,357,782.
• United Therapeutics seeks to enjoin Liquidia from commercializing YUTREPIA for PAH and PH-ILD.
• A motion for temporary restraining order and preliminary injunction to block Liquidia's commercial launch is pending with the Court, with oral argument held on May 20, 2025.

Stakeholder Impact

• **Patients:** Gain access to a new, potentially best-in-class dry-powder treprostinil treatment option for PAH and PH-ILD, designed for ease of use and deep-lung delivery.
• **Physicians:** Have a newly introduced option for inhaled treprostinil, potentially making it easier to start and maintain patients on treatment.
• **Shareholders:** Benefit from the significant value creation potential of FDA approval and impending commercial launch, though this is subject to risks from ongoing litigation.
• **Competitors (e.g., United Therapeutics):** Face new competition in the treprostinil market, particularly with a differentiated dry-powder formulation.

Next Steps

• Begin commercializing YUTREPIA for the treatment of PAH and PH-ILD as soon as possible.
• Host a live webcast on May 27, 2025, to provide an update on YUTREPIA commercial launch preparations.
• Vigorously defend against all new and ongoing litigation initiated by United Therapeutics.

Key Dates

Recommendation

Keywords

YUTREPIA, treprostinil, PAH, PH-ILD, FDA approval, Liquidia Corporation, pulmonary arterial hypertension, pulmonary hypertension associated with interstitial lung disease, biopharmaceutical, rare disease, PRINT technology, drug approval, patent litigation